234 related articles for article (PubMed ID: 29857941)
1. GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution.
Grondin R; Littrell OM; Zhang Z; Ai Y; Huettl P; Pomerleau F; Quintero JE; Andersen AH; Stenslik MJ; Bradley LH; Lemmon J; O'Neill MJ; Gash DM; Gerhardt GA
Neuropharmacology; 2019 Mar; 147():28-36. PubMed ID: 29857941
[TBL] [Abstract][Full Text] [Related]
2. Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.
Smith RC; O'Bryan LM; Mitchell PJ; Leung D; Ghanem M; Wilson JM; Hanson JC; Sossick S; Cooper J; Huang L; Merchant KM; Lu J; O'Neill MJ
Exp Neurol; 2015 May; 267():165-76. PubMed ID: 25771799
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain.
Hadaczek P; Johnston L; Forsayeth J; Bankiewicz KS
Neuropharmacology; 2010 Jun; 58(7):1114-21. PubMed ID: 20153340
[TBL] [Abstract][Full Text] [Related]
4. Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.
Hamilton JF; Morrison PF; Chen MY; Harvey-White J; Pernaute RS; Phillips H; Oldfield E; Bankiewicz KS
Exp Neurol; 2001 Mar; 168(1):155-61. PubMed ID: 11170730
[TBL] [Abstract][Full Text] [Related]
5. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R; Gash DM
J Neurol; 1998 Nov; 245(11 Suppl 3):P35-42. PubMed ID: 9808338
[TBL] [Abstract][Full Text] [Related]
6. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
7. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease.
Tanriover G; Seval-Celik Y; Ozsoy O; Akkoyunlu G; Savcioglu F; Hacioglu G; Demir N; Agar A
Folia Histochem Cytobiol; 2010 Sep; 48(3):434-41. PubMed ID: 21071351
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
9. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism.
Lindholm P; Saarma M
Mol Psychiatry; 2022 Mar; 27(3):1310-1321. PubMed ID: 34907395
[TBL] [Abstract][Full Text] [Related]
10. Induction of glial cell line-derived neurotrophic factor by the squamosamide derivative FLZ in astroglia has neuroprotective effects on dopaminergic neurons.
Bao XQ; Wang L; Yang HY; Hou LY; Wang QS; Zhang D
Brain Res Bull; 2020 Jan; 154():32-42. PubMed ID: 31669104
[TBL] [Abstract][Full Text] [Related]
11. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
Kobayashi S; Ogren SO; Hoffer BJ; Olson L
Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
[TBL] [Abstract][Full Text] [Related]
13. Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.
Runeberg-Roos P; Piccinini E; Penttinen AM; Mätlik K; Heikkinen H; Kuure S; Bespalov MM; Peränen J; Garea-Rodríguez E; Fuchs E; Airavaara M; Kalkkinen N; Penn R; Saarma M
Neurobiol Dis; 2016 Dec; 96():335-345. PubMed ID: 27425888
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons.
Akerud P; Alberch J; Eketjäll S; Wagner J; Arenas E
J Neurochem; 1999 Jul; 73(1):70-8. PubMed ID: 10386956
[TBL] [Abstract][Full Text] [Related]
15. Long-term exposure to GDNF induces dephosphorylation of Ret, AKT, and ERK1/2, and is ineffective at protecting midbrain dopaminergic neurons in cellular models of Parkinson's disease.
Mesa-Infante V; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Barroso-Chinea P
Mol Cell Neurosci; 2022 Jan; 118():103684. PubMed ID: 34826608
[TBL] [Abstract][Full Text] [Related]
16. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
17. Neurturin effects on nigrostriatal dopamine release and content: comparison with GDNF.
Cass WA; Peters LE
Neurochem Res; 2010 May; 35(5):727-34. PubMed ID: 20119638
[TBL] [Abstract][Full Text] [Related]
18. Functional recovery in parkinsonian monkeys treated with GDNF.
Gash DM; Zhang Z; Ovadia A; Cass WA; Yi A; Simmerman L; Russell D; Martin D; Lapchak PA; Collins F; Hoffer BJ; Gerhardt GA
Nature; 1996 Mar; 380(6571):252-5. PubMed ID: 8637574
[TBL] [Abstract][Full Text] [Related]
19. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Administration of chitosan-Coated Nanostructured Lipid Carriers Loaded with GDNF Improves Behavioral and Histological Recovery in a Partial Lesion Model of Parkinson's Disease.
Gartziandia O; Herrán E; Ruiz-Ortega JA; Miguelez C; Igartua M; Lafuente JV; Pedraz JL; Ugedo L; Hernández RM
J Biomed Nanotechnol; 2016 Dec; 12(12):2220-30. PubMed ID: 29372975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
